Abstract

Mitochondrial dysfunction with oxidative stress contributes to metabolic dysfunction-associated steatotic liver disease (MASLD) progression. We aimed to evaluate the fibrosis predictive efficacy of a novel non-invasive diagnostic panel using metabolic stress biomarkers. From a population-based general cohort, 144 subjects with MASLD were recruited in the development group and underwent magnetic resonance imaging-based liver examinations, anthropometric and laboratory tests. As an external validation group, 41 patients enrolled in a biopsy-evaluated MASLD cohort participated in this study. Liver fat content and stiffness were measured by magnetic resonance (MR) imaging-proton density fat fraction and MR elastography (MRE), respectively. Serologic stress biomarkers were quantitated by ELISA. Multivariate regression showed that waist-to-height ratio, growth differentiation factor-15 (GDF15), γ-glutamyltransferase, decorin, and alkaline-phosphatase were independent predictors of hepatic fibrosis (rank-ordered by Wald). The area under receiver-operator characteristics curve [AUROC (95% CI)) of the metabolic stress index for fibrosis (MSI-F) was 0.912 (0.85‒0.98) and 0.977 (0.92‒1.00) in development and validation groups, respectively. MSI-F also had better diagnostic accuracy (82.6‒92.4%) than other fibrosis indices in the both study cohorts. MSI-F consistently differentiated fibrosis severities across cohorts of MRE-evaluated general population and biopsy-proven patients with MASLD, while other indices showed no or less discrimination. MSI-F, as a novel non-invasive index based on a stress-stimulated protective hormone GDF15 and decorin, effectively predicted hepatic fibrosis. Furthermore, MSI-F may serve as pre-screening tool to increase the population that could be excluded from further evaluation, reducing unnecessary invasive investigations more effectively than other indices.

Details

Title
Elevated serum growth differentiation factor 15 and decorin predict the fibrotic progression of metabolic dysfunction-associated steatotic liver disease
Author
Chang, Jae Seung 1 ; Ahn, Jhii-Hyun 2 ; Kim, Moon Young 3 ; Park, Kyu-Sang 4 

 Hannam University, Department of Sports Science, College of Life Science and Nano Technology, Daejeon, South Korea (GRID:grid.411970.a) (ISNI:0000 0004 0532 6499); Yonsei University Wonju College of Medicine, Mitohormesis Research Center, Wonju, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); Yonsei University Wonju College of Medicine, Department of Physiology, Wonju, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454) 
 Yonsei University Wonju College of Medicine, Department of Radiology, Wonju, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454) 
 Yonsei University Wonju College of Medicine, Mitohormesis Research Center, Wonju, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); Yonsei University Wonju College of Medicine, Department of Internal Medicine, Wonju, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); Yonsei University Wonju College of Medicine, Regeneration Medicine Research Center, Wonju, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454) 
 Yonsei University Wonju College of Medicine, Mitohormesis Research Center, Wonju, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); Yonsei University Wonju College of Medicine, Department of Physiology, Wonju, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454) 
Pages
27527
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3126818158
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.